Description
Join us for a special webinar on World Ovarian Cancer Day, titled "Gynaecologist’s Guide to Ovarian Cancer." This expert-led session will delve into the latest advancements in early diagnosis, risk stratification, and evidence-based management of ovarian cancer. Tailored for gynecologists and healthcare professionals, the session will also explore real-world case discussions and multidisciplinary treatment approaches. Let’s come together to raise awareness and empower clinicians in the fight against this silent but deadly disease.
Summary Listen
- Ovarian cancer, a multifactorial disease, primarily affects women aged 50 and above, particularly postmenopausal women, though it can occur in younger individuals. Family history of ovarian, breast, or related cancers increases the risk, often due to genetic mutations or hormonal influences. Genetic mutations such as BRCA1, BRCA2, and Lynch syndrome, where multiple family members develop different types of cancers, are significant risk factors. A woman's reproductive history, including never having been pregnant or breastfed, early menarche, late menopause, and obesity, can also contribute to the likelihood of developing ovarian cancer.
- Diagnosis relies heavily on clinical assessment, including a detailed patient history, physical examination, and family history. Tumor markers, while not definitive, can aid in diagnosis, especially when combined with ultrasound findings. Risk of Malignancy Index (RMI) and similar algorithms incorporating menopausal status, CA125 levels, and ultrasound features are commonly used in evaluation. Other tumor markers like HE4 can assist in diagnosis and monitoring, but none are entirely specific.
- Transvaginal ultrasound plays a crucial role, requiring skilled interpretation to identify features like solid areas, papillary projections, thick septations, and increased vascularity. CT scans, MRIs, and PET-CT scans are used to assess metastasis. Diagnosis is confirmed via biopsy during surgery, which allows for histopathological analysis and genetic testing (BRCA1/2, Lynch syndrome).
- Fertility preservation is a critical consideration for women diagnosed with early-stage ovarian cancer. Options include oocyte cryopreservation, embryo cryopreservation, and ovarian tissue cryopreservation. Surgical options like unilateral salpingo-oophorectomy or cystectomy aim to preserve ovarian function whenever possible. Fertility preservation decisions should be made in consultation with oncologists and documented thoroughly.
- Post-treatment surveillance involves regular history taking, physical examinations, and CA125 monitoring every 3-6 months for five years. Imaging studies are used when clinically indicated or when CA125 levels rise. Psychological support is essential for patients coping with the emotional impact of cancer and its treatment. Genetic counseling is crucial to assess risk for other cancers and to inform family screening.
- Primary care providers are vital in managing menopause symptoms resulting from treatment-induced ovarian failure, monitoring bone health, and addressing fatigue, anxiety, and depression. Hormone replacement therapy (HRT) can be considered in certain cases, contingent upon the tumor's hormone sensitivity and in consultation with an oncologist. Alternative options are available for patients unable to use HRT.
Sample Certificate
About the Speakers
Dr. Josevania Martins
Consultant Gynecologist and Fertility Specialist, Vania Healthcare LTD, London, U.K
Financial Disclosure
Comments
Comments
You must be logged in to leave a comment.